Open Payments

THE NEBRASKA MEDICAL CENTER

Type
Teaching hospital
Where
OMAHA, NE
Medicare CCN
280013
Received
$971,934 in 312 records, 2019 ($224,531 general, $747,402 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment100$224,531
2019Research payment212$747,402

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC144$236,0632019
Amgen Inc.1$131,5332019
Clovis Oncology, Inc.1$100,0002019
BioFire Diagnostics, LLC12$58,8282019
PFIZER INC.1$57,7832019
Osteomed LLC10$50,5002019
TransMedics, Inc.3$42,4752019
Surmodics, Inc.24$41,1292019
Mallinckrodt Enterprises LLC8$37,7272019
Biocompatibles, Inc.1$37,0742019
Philips North America LLC4$32,0672019
Artivion, Inc.4$30,4052019
OPKO Pharmaceuticals, LLC2$25,0332019
Agios Pharmaceuticals, Inc.6$21,1692019
Tandem Diabetes Care, Inc.56$16,7002019
INSTRUMENTATION LABORATORY COMPANY3$12,6052019
Insulet Corporation17$12,5502019
Novartis Pharmaceuticals Corporation1$7,5872019
W. L. Gore & Associates, Inc.1$5,0402019
bioMerieux Inc1$4,6692019
AstraZeneca Pharmaceuticals LP1$2,9462019
Linvatec Corporation1$2,5932019
Shionogi Inc1$2,3522019
ZOLL Medical Corporation2$1,5002019
APPLIED MEDICAL TECHNOLOGY INC1$4002019
C. R. Bard, Inc. & Subsidiaries1$4002019
MOLNLYCKE HEALTH CARE US, LLC1$4002019
Masimo Corporation2$2252019
OXFORD GENE TECHNOLOGY INC1$1492019
Zimmer Biomet Holdings, Inc.1$252019

By nature of payment

NatureRecordsAmount
Research payment212$747,402
Grant12$153,093
Consulting Fee5$34,419
Compensation for services other than consulting, including serving as faculty or as a speaker at a v74$29,650
Gift2$4,694
Space rental or facility fees (teaching hospital only)4$2,300
Education2$225
Food and Beverage1$149

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Masimo Corporation$143EducationIn-kind items and servicesSET and rainbow SET Device, Devices2019
2019-12-31Masimo Corporation$82EducationIn-kind items and servicesEMMA and ISA Device, Devices2019
2019-12-31Zimmer Biomet Holdings, Inc.$25GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-30Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-26Philips North America LLC$6,092Consulting FeeCash or cash equivalentHealthTec Device, Cardiology/Vascular Diseases2019
2019-12-26Merck Sharp & Dohme LLC$607Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-12-26Merck Sharp & Dohme LLC$45Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-12-23Philips North America LLC$12,962Consulting FeeCash or cash equivalentHealthTec Device, Cardiology/Vascular Diseases2019
2019-12-23Philips North America LLC$6,919Consulting FeeCash or cash equivalentHealthTec Device, Cardiology/Vascular Diseases2019
2019-12-23Philips North America LLC$6,092Consulting FeeCash or cash equivalentHealthTec Device, Cardiology/Vascular Diseases2019
2019-12-19Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-19Merck Sharp & Dohme LLC$166Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-12-19Merck Sharp & Dohme LLC$91Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-12-19Merck Sharp & Dohme LLC$58Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-12-13Merck Sharp & Dohme LLC$303Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-12-11PFIZER INC.$57,783Research paymentIn-kind items and servicesBESPONSA Biological, ONCOLOGYA PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT2019
2019-12-11Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-12-10BioFire Diagnostics, LLC$4,060Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-12-05Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-12-04C. R. Bard, Inc. & Subsidiaries$400Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-12-04Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-04Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-03BioFire Diagnostics, LLC$4,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-12-03Merck Sharp & Dohme LLC$91Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-29Merck Sharp & Dohme LLC$16,239Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj2019
2019-11-25Insulet Corporation$625Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-11-22Merck Sharp & Dohme LLC$27,431Research paymentCash or cash equivalentPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-22Merck Sharp & Dohme LLC$291Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-21Merck Sharp & Dohme LLC$455Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-21Merck Sharp & Dohme LLC$137Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-21BioFire Diagnostics, LLC$103Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-11-21Merck Sharp & Dohme LLC$87Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-21Merck Sharp & Dohme LLC$46Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-11-20Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-11-15Artivion, Inc.$4,300Research paymentCash or cash equivalentPhotoFix Device, Cardiology and Vascular DiseasesPost-market, prospective evaluation of PHOTO-oxidized decellularized bovine pericardium used as a patch in Vascular repa2019
2019-11-12Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-11-08W. L. Gore & Associates, Inc.$5,040Research paymentCash or cash equivalentProduct in Development Device, DevicesGore Research and Development2019
2019-11-08APPLIED MEDICAL TECHNOLOGY INC$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBridle Device, Enteral2019
2019-11-04ZOLL Medical Corporation$750Space rental or facility fees (teaching hospital only)Cash or cash equivalent Device, DEFIBRILLATOR2019
2019-11-04Merck Sharp & Dohme LLC$455Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-11-04Merck Sharp & Dohme LLC$45Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-31Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-10-30Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-30Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-30Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-28Merck Sharp & Dohme LLC$413Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-10-18Mallinckrodt Enterprises LLC$1,285Research paymentCash or cash equivalentACTHAR Biological, AUTOIMMUNE AND RARE DISEASEA DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS2019
2019-10-17Merck Sharp & Dohme LLC$455Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-17Merck Sharp & Dohme LLC$91Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-10Osteomed LLC$5,250GrantCash or cash equivalent Device, NEURO-OTHER2019
2019-10-10Osteomed LLC$5,000GrantCash or cash equivalent Device, CMF-OTHER2019
2019-10-10Osteomed LLC$5,000GrantCash or cash equivalent Device, CMF-OTHER2019
2019-10-09TransMedics, Inc.$20,035Research paymentCash or cash equivalentOrgan Care System Device, DevicePROTECT LIVER2019
2019-10-09Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-09Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-09Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-09Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-09Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-08Merck Sharp & Dohme LLC$696Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$117Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$103Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$78Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$60Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$41Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$12Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$6Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-04Mallinckrodt Enterprises LLC$3,486Research paymentCash or cash equivalentACTHAR Biological, AUTOIMMUNE AND RARE DISEASEA DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS2019
2019-10-02Merck Sharp & Dohme LLC$21,775Research paymentCash or cash equivalentPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-10-02Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-02Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-02Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-02Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-01BioFire Diagnostics, LLC$4,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-10-01BioFire Diagnostics, LLC$4,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-10-01Insulet Corporation$225Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-09-27Merck Sharp & Dohme LLC$776Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-27Merck Sharp & Dohme LLC$303Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-27Merck Sharp & Dohme LLC$45Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-25Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-09-24Mallinckrodt Enterprises LLC$7,538Research paymentCash or cash equivalentACTHAR Biological, AUTOIMMUNE AND RARE DISEASEA DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS2019
2019-09-18Surmodics, Inc.$945Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-09-18Surmodics, Inc.$945Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-09-18Surmodics, Inc.$945Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-09-18Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-09-13TransMedics, Inc.$3,591Research paymentCash or cash equivalentOrgan Care System Device, DeviceEXPAND LUNG II2019
2019-09-12Merck Sharp & Dohme LLC$759Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-11Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-09-10Merck Sharp & Dohme LLC$348Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$173Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$140Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$124Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$118Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$103Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$78Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$72Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$60Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$18Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$10Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$8Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$8Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-10Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-09-05Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-08-29Insulet Corporation$625Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-08-28Merck Sharp & Dohme LLC$6,951Research paymentCash or cash equivalentPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-26BioFire Diagnostics, LLC$9,111Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-08-15Tandem Diabetes Care, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-08-15Merck Sharp & Dohme LLC$303Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-15Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-08-14Shionogi Inc$2,352Consulting FeeCash or cash equivalentFetroja Drug, Infections and Infectious Diseases2019
2019-08-14Insulet Corporation$625Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-08-11Artivion, Inc.$6,595Research paymentCash or cash equivalentPhotoFix Device, Cardiology and Vascular DiseasesPost-market, prospective evaluation of PHOTO-oxidized decellularized bovine pericardium used as a patch in Vascular repa2019
2019-08-08Merck Sharp & Dohme LLC$316Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$158Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$140Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$103Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$103Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$103Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$13Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-08-02Linvatec Corporation$2,593GrantIn-kind items and servicesAIRSEAL Device, GENERAL SURGERY2019
2019-07-26Merck Sharp & Dohme LLC$8,339Research paymentCash or cash equivalentPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-25Merck Sharp & Dohme LLC$395Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-07-24Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-07-24Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-07-18OPKO Pharmaceuticals, LLC$13,356Research paymentCash or cash equivalentnone DrugSafety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency2019
2019-07-18Merck Sharp & Dohme LLC$759Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-17Surmodics, Inc.$1,545Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-07-17Surmodics, Inc.$1,545Research paymentCash or cash equivalentSurVeil Device, Drug-Coated BalloonTRANSCEND2019
2019-07-10Merck Sharp & Dohme LLC$455Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Tandem Diabetes Care, Inc.$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-07-10Tandem Diabetes Care, Inc.$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-07-10Merck Sharp & Dohme LLC$183Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$158Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$103Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$60Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-10Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-07-08Osteomed LLC$5,250GrantCash or cash equivalent Device, NEURO-OTHER2019
2019-07-08Osteomed LLC$5,000GrantCash or cash equivalent Device, CMF-OTHER2019
2019-07-08Osteomed LLC$5,000GrantCash or cash equivalent Device, CMF-OTHER2019
2019-07-03Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-06-27Insulet Corporation$400Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-06-26Merck Sharp & Dohme LLC$6,715Research paymentCash or cash equivalentPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-26Tandem Diabetes Care, Inc.$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-06-26Tandem Diabetes Care, Inc.$200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-06-25Clovis Oncology, Inc.$100,000GrantCash or cash equivalentRubraca Drug, Oncology2019
2019-06-25Merck Sharp & Dohme LLC$21,652Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-06-25AstraZeneca Pharmaceuticals LP$2,946Research paymentCash or cash equivalentTUDORZA PRESSAIR Drug, RespiratoryDouble blind Randomized Placebo controlled Parallel group Study to Evaluate the Effect of Aclidinium Bromide on Long Ter2019
2019-06-25Merck Sharp & Dohme LLC$642Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju2019
2019-06-21Agios Pharmaceuticals, Inc.$10,483Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-06-21Agios Pharmaceuticals, Inc.$6,150Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-06-21Agios Pharmaceuticals, Inc.$1,890Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-06-21Agios Pharmaceuticals, Inc.$1,260Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-06-21Agios Pharmaceuticals, Inc.$756Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-06-21Agios Pharmaceuticals, Inc.$630Research paymentCash or cash equivalentA PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA2019
2019-06-18Amgen Inc.$131,533Research paymentCash or cash equivalentKyprolis Biological, OncologyA Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome In2019
2019-06-15OXFORD GENE TECHNOLOGY INC$149Food and BeverageIn-kind items and services2019
2019-06-10Merck Sharp & Dohme LLC$1,076Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$316Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$235Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$235Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$141Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$124Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$94Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$72Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$72Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$59Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$59Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$27Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$14Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$12Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$8Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$7Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$6Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019
2019-06-10Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesPREVYMIS Drug, INFECTIOUS DISEASEA Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm2019

The latest 200 records of 312.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Douglas CountyOmaha city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Omaha, NE, county Douglas County, NE, state Nebraska; placed by its city name.

MeasurePlace (city or town)
Omaha, NE
County
Douglas County, NE
State
Nebraska
Population B01003488,837590,7361,978,707
Population, 2020 census P1486,051584,5261,961,504
Median age B0100235.335.637.2
Under 18 B0100124.2%25.3%24.5%
65 and over B0100114.5%14.1%16.7%
Households B11001201,698238,430797,847
Foreign born B0500211.3%10.6%8.0%
Median household income B19013$73,201$80,391$76,475
Median family income B19113$99,432$108,805$99,751
Per capita income B19301$43,638$46,334$41,751
Poverty rate B1700113.5%11.8%10.6%
Unemployment rate B230254.2%3.8%3.0%
Civilian labor force B23025264,681320,0241,056,746
Mean commute (minutes) B0801319.620.019.2
Bachelor's degree or higher B1500340.1%42.1%34.6%
Housing units B25001213,023251,553863,444
Owner-occupied B2500357.4%61.5%66.5%
Renters B2500342.6%38.5%33.5%
Median home value B25077$245,500$266,100$238,600
Median gross rent B25064$1,187$1,201$1,072
White, not Hispanic B0300263.4%65.8%75.3%
Black B0300211.4%10.2%4.6%
Hispanic or Latino B0300216.2%14.5%12.7%
Asian B030024.0%4.4%2.6%
American Indian and Alaska Native B030020.2%0.2%0.6%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Omaha, NE.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.